Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28430
Abstract: Nirmatrelvir/ritonavir (NMV‐r) is an effective anti‐SARS‐CoV‐2 agent and has been recommended in the treatment of nonhospitalized patients with COVID‐19. In rare occasions, some patients experience virologic and symptomatic rebound after initial resolution, which we call… read more here.
Keywords: covid rebound; coronavirus disease; nirmatrelvir ritonavir; rebound ... See more keywords